Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics
Dyadic Applied BioSolutions (NASDAQ:DYAI) announced a commercial CRISPR/Cas9 license from ERS Genomics on Nov 10, 2025, granting access to ERS’ global patent portfolio to support genetic engineering across Dyadic’s C1 and Dapibus bioproduction platforms. The license is intended to accelerate strain engineering, pathway optimization, and integration of CRISPR gene editing into Dyadic’s internal pipeline and partner projects across life sciences, food & nutrition, and bio-industrial sectors.
ERS Genomics holds a portfolio of 100+ patents and reports 150+ licenses worldwide; financial terms of this agreement were not disclosed.
Dyadic Applied BioSolutions (NASDAQ:DYAI) ha annunciato una licenza commerciale CRISPR/Cas9 da ERS Genomics in data 10 novembre 2025, concedendo l'accesso al portafoglio globale di brevetti di ERS per supportare l'ingegneria genetica sulle piattaforme di bioproduzione C1 e Dapibus di Dyadic. La licenza è pensata per accelerare l'ingegneria delle ceppo, l'ottimizzazione dei percorsi e l'integrazione dell'editing CRISPR nel pipeline interno di Dyadic e nei progetti partner nei settori delle scienze della vita, alimentare e bio-industriale.
ERS Genomics detiene un portfolio di oltre 100 brevetti e riporta oltre 150 licenze in tutto il mondo; i termini finanziari di questo accordo non sono stati divulgati.
Dyadic Applied BioSolutions (NASDAQ:DYAI) anunció una licencia comercial de CRISPR/Cas9 de ERS Genomics el 10 de noviembre de 2025, otorgando acceso al portafolio global de patentes de ERS para apoyar la ingeniería genética en las plataformas de bioproducción C1 y Dapibus de Dyadic. La licencia está destinada a acelerar la ingeniería de cepas, la optimización de rutas y la integración de la edición CRISPR en la pipeline interna de Dyadic y proyectos de sus socios en los sectores de ciencias de la vida, alimentación y nutrición y bioindustrial.
ERS Genomics posee un portafolio de más de 100 patentes y reporta más de 150 licencias en todo el mundo; los términos financieros de este acuerdo no fueron revelados.
Dyadic Applied BioSolutions (NASDAQ:DYAI)은 ERS Genomics로부터의 상용 CRISPR/Cas9 라이선스를 2025년 11월 10일에 발표하여, Dyadic의 C1 및 Dapibus 생물생산 플랫폼 전반에 걸친 유전 공학 지원을 위해 ERS의 전 세계 특허 포트폴리오에 대한 접근을 부여합니다. 이 라이선스는 균주 공학 가속화, 경로 최적화, CRISPR 유전자 편집을 Dyadic 내부 파이프라인 및 생명과학, 식품 및 영양, 바이오산업 부문의 파트너 프로젝트에 통합하는 것을 목적으로 합니다.
ERS Genomics는 100개 이상의 특허 포트폴리오를 보유하고 있으며 전 세계적으로 150개 이상의 라이선스를 보고합니다. 이 계약의 재무 조건은 공개되지 않았습니다.
Dyadic Applied BioSolutions (NASDAQ:DYAI) a annoncé une licence commerciale de CRISPR/Cas9 de ERS Genomics le 10 novembre 2025, accordant l'accès au portefeuille mondial de brevets d'ERS pour soutenir l'ingénierie génétique sur les plateformes de bioproduction C1 et Dapibus de Dyadic. La licence vise à accélérer l'ingénierie des souches, l'optimisation des voies et l'intégration de l'édition CRISPR dans le pipeline interne de Dyadic et les projets partenaires dans les secteurs des sciences de la vie, de l'alimentation et de la bio-industrie.
ERS Genomics détient un portefeuille de plus de 100 brevets et fait état de plus de 150 licences dans le monde ; les conditions financières de cet accord n'ont pas été divulguées.
Dyadic Applied BioSolutions (NASDAQ:DYAI) kündigte eine kommerzielle CRISPR/Cas9-Lizenz von ERS Genomics am 10. November 2025 an und gewährt Zugriff auf das globale Patentportfolio von ERS zur Unterstützung der Gentechnik auf Dyadics C1- und Dapibus-Bioprozessplattformen. Die Lizenz zielt darauf ab, die Stammentwicklung zu beschleunigen, Wege zu optimieren und die CRISPR-Genbearbeitung in Dyadics interne Pipeline sowie Partnerprojekte in den Bereichen Life Sciences, Lebensmittel & Ernährung und Bio-Industrie zu integrieren.
ERS Genomics hält ein Portfolio von über 100 Patenten und meldet weltweit mehr als 150 Lizenzen; Die finanziellen Bedingungen dieser Vereinbarung wurden nicht offengelegt.
Dyadic Applied BioSolutions (NASDAQ:DYAI) أعلنت عن ترخيص تجاري لـ CRISPR/Cas9 من ERS Genomics في 10 نوفمبر 2025، ما يمنح الوصول إلى محفظة براءات ERS العالمية لدعم الهندسة الوراثية عبر منصات الإنتاج الحيوي C1 و Dapibus الخاصة بـ Dyadic. يهدف الترخيص إلى تسريع هندسة السلالات، وتحسين المسارات، ودمج تحرير جين CRISPR في خط أنابيب Dyadic الداخلي ومشاريع الشركاء عبر قطاعات علوم الحياة، الغذاء والتغذية، والبيو-صناعي.
يمتلك ERS Genomics محفظة تحتوي على أكثر من 100 براءة اختراع ويبلغ عن أكثر من 150 ترخيصاً على مستوى العالم؛ لم تُكشف الشروط المالية لهذا الاتفاق.
- None.
- None.
Insights
Dyadic gains commercial access to ERS Genomics' CRISPR/Cas9 patents, broadening its strain‑engineering toolkit.
By securing a commercial license to ERS Genomics' CRISPR/Cas9 patent portfolio, Dyadic Applied BioSolutions obtains rights to apply a foundational gene‑editing platform across its proprietary C1 and Dapibus production platforms. This allows Dyadic to integrate CRISPR‑based edits into strain engineering and pathway optimization workflows to target productivity, product quality, and customized strains for partners.
Benefits depend on effective technical integration, freedom‑to‑operate within the licensed scope, and the firm's ability to translate edits into measurable production gains. The announcement confirms ERS holds a portfolio of 100+ patents worldwide and reports >150 existing licenses; financial terms were not disclosed, so near‑term balance‑sheet impact is unknown.
Watch for concrete milestones such as demonstrations of improved strain performance, partner engagements using CRISPR‑edited strains, and any future disclosure of licensing fees or timelines; short‑term evidence should appear within the next
JUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today announced a CRISPR/Cas9 license agreement. This agreement grants Dyadic access to ERS’ CRISPR/Cas9 patent portfolio, enhancing Dyadic’s ability to accelerate strain engineering and pathway optimization to enhance productivity, product quality, and innovation across its proprietary bioproduction platforms.
“Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s proprietary C1 and Dapibus production platforms,” stated Joe Hazelton, President and COO, Dyadic Applied BioSolutions. “This agreement supports both Dyadic’s internal product pipeline and the customized production strains we develop for our partners. By integrating CRISPR-based gene editing into our development workflow, we can boost strain performance, efficiency, and adaptability, delivering greater value across the life sciences, food and nutrition, and bio-industrial sectors.”
John E. Milad, CEO, ERS Genomics, commented: “Dyadic’s work illustrates how broad access to foundational CRISPR/Cas9 technology can drive efficiencies across life sciences and bio-industrial sectors. This agreement reflects our commitment to enabling responsible and equitable use of CRISPR/Cas9, ensuring that organizations across the sector can apply this Nobel Prize-winning technology with confidence.”
CRISPR gene editing is a genetic engineering technique in molecular biology by which the genomes of living organisms may be modified. It is based on a simplified version of the bacterial CRISPR-Cas9 antiviral defense system. The development of the technique earned biochemists Emmanuelle Charpentier (one of the founders of ERS Genomics) and Jennifer Doudna the Nobel Prize in Chemistry in 2020.
ERS Genomics provides foundational licenses to its Nobel prize-winning CRISPR/Cas9 technology to companies integrating it into their commercial programs. With a portfolio of 100+ patents worldwide, ERS’ IP covers CRISPR/Cas9 applications across all cell types, including mammalian cells, bacteria, archaea, yeasts, and algae, as well as extracellular uses such as cell-free systems and synthetic biology applications. ERS Genomics licenses these patents via its direct license from Professor Emmanuelle Charpentier and now has over 150 licenses in place worldwide.
Financial details of the agreement were not disclosed.
About Dyadic Applied BioSolutions
Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s C1 and Dapibus™ expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs. For more information about Dyadic, please visit www.dyadic.com.
About ERS Genomics
ERS Genomics provides access to the foundational CRISPR/Cas9 intellectual property estate (the ‘CVC Patents’) co-owned by Prof Emmanuelle Charpentier. A license to the CVC Patents is essential for ensuring freedom to operate when practicing the use of CRISPR/Cas9 in all cells. The CVC Patents include over 130 patents worldwide, with over 50 patents in the US alone, covering over 1,400 claims.
Non-exclusive licenses to the CVC Patents are available from ERS Genomics for both research use and commercial applications outside of the direct use of CRISPR as a human therapeutic. ERS Genomics’ licenses support a wide range of applications, including life sciences research tools, kits and reagents; discovery of novel targets for therapeutic intervention; development of cell lines for drug discovery and screening; bioproduction of antibodies and therapeutic proteins; advancements in companion animal and livestock health; and diverse synthetic biology applications such as producing enzymes, biofuels and chemicals.
Current licensees include GSK, Merck, Bayer, ThermoFisher Scientific, Corteva, Lonza, Taconic, Danaher, PerkinElmer, Charles River Laboratories, Synthego, and Cargill. For additional information please visit www.ersgenomics.com.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic’s control. These factors include, but are not limited to, the following: (i) our history of net losses; (ii) market and regulatory acceptance of our microbial protein production platforms and other technologies; (iii) failure to commercialize our microbial protein production platforms or our other technologies; (iv) competition, including from alternative technologies; (v) the results of nonclinical studies and clinical trials; (vi) our capital needs; (vii) changes in global economic and financial conditions; (viii) our reliance on information technology; (ix) our dependence on third parties; (x) government regulations and environmental, social and governance issues; (xi) intellectual property risks; and (xii) our ability to comply with the listing standards of the Nasdaq Stock Market LLC. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com. All forward-looking statements speak only as of the date made, and except as required by applicable law, Dyadic assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in our expectations.
Media contacts:
Dyadic Applied BioSolutions:
Ping Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com
ERS Genomics:
5654 & Company (ERSGenomics@5654.co.uk)
Matthew Neal (+44 7917 800 011)
Charlotte Dawson (+44 7810 406 284)
FAQ
What did Dyadic (DYAI) announce on November 10, 2025 regarding CRISPR?
How does the ERS Genomics license affect Dyadic’s strain development for DYAI?
Does the Dyadic CRISPR license include financial terms for DYAI shareholders?
What scope of CRISPR patents does ERS provide to Dyadic (DYAI)?
Will the ERS license change Dyadic’s commercial offerings for DYAI partners?
Who are the founders or notable figures associated with the CRISPR technology licensed by Dyadic (DYAI)?
